



## Calcium and mitochondrial metabolism in ceramide-induced cardiomyocyte death



Valentina Parra<sup>a,b,1</sup>, Francisco Moraga<sup>a,1</sup>, Jovan Kuzmichic<sup>a</sup>, Camila López-Crisosto<sup>a</sup>, Rodrigo Troncoso<sup>a</sup>, Natalia Torrealba<sup>a</sup>, Alfredo Criollo<sup>b</sup>, Jessica Díaz-Elizondo<sup>a</sup>, Beverly A. Rothermel<sup>b</sup>, Andrew F.G. Quest<sup>a,\*</sup>, Sergio Lavandero<sup>a,b,\*\*</sup>

<sup>a</sup> Centro de Estudios Moleculares de la Célula, Facultad de Ciencias Químicas y Farmacéuticas & Facultad Medicina, Universidad de Chile, Santiago, Chile

<sup>b</sup> Department of Internal Medicine (Cardiology Division) and Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX, USA

### ARTICLE INFO

#### Article history:

Received 5 November 2012

Received in revised form 4 April 2013

Accepted 8 April 2013

Available online 16 April 2013

#### Keywords:

Ceramide

Metabolism

Mitochondrial dynamics

Ca<sup>2+</sup>

Cell death

Cardiomyocyte

### ABSTRACT

Ceramides are important intermediates in the biosynthesis and degradation of sphingolipids that regulate numerous cellular processes, including cell cycle progression, cell growth, differentiation and death. In cardiomyocytes, ceramides induce apoptosis by decreasing mitochondrial membrane potential and promoting cytochrome-c release. Ca<sup>2+</sup> overload is a common feature of all types of cell death. The aim of this study was to determine the effect of ceramides on cytoplasmic Ca<sup>2+</sup> levels, mitochondrial function and cardiomyocyte death. Our data show that C<sub>2</sub>-ceramide induces apoptosis and necrosis in cultured cardiomyocytes by a mechanism involving increased Ca<sup>2+</sup> influx, mitochondrial network fragmentation and loss of the mitochondrial Ca<sup>2+</sup> buffer capacity. These biochemical events increase cytosolic Ca<sup>2+</sup> levels and trigger cardiomyocyte death via the activation of calpains.

© 2013 Elsevier B.V. All rights reserved.

### 1. Introduction

Thudichum (1884) referred to sphingolipids (from the Greek Σφινξ; sphinx) as a peculiar group of lipids because of their enigmatic nature [1]. Ceramides represent the structural backbone common to all sphingolipids [2]. Moreover, they regulate several key cellular processes, including cell cycle, cell growth and differentiation, as well as cell death. Intracellular de novo synthesis of ceramides occurs in response to cytokines, environmental stress and chemotherapeutic agents [2]. Ceramides have also been shown to trigger different forms of cell death, depending on cell context. In this respect, it should be noted that they stimulate necrosis in lymphoid cells by increasing ROS formation and promoting ATP depletion [3].

**Abbreviations:** CCCP, carbonyl cyanide *m*-chlorophenylhydrazine; C<sub>2</sub>-ceramide, D-erythro-sphingosine-N-acetate; CsA, cyclosporin A; cyt-c, cytochrome-c; DH-C<sub>2</sub>, dihydro-D-erythro-sphingosine-N-acetate; ER, endoplasmic reticulum; LDH, lactic dehydrogenase; MP, methyl pyruvate; TMRM, tetramethylrhodamine methyl ester; PI, propidium iodide;  $\psi_{mt}$ , mitochondrial membrane potential; TNF- $\alpha$ , tumor necrosis factor alpha

\* Correspondence to: A.F.G. Quest, Facultad de Medicina, Universidad de Chile, Independencia 1027, Santiago 8389100, Chile.

\*\* Correspondence to: S. Lavandero, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile. Olivos 1007, Santiago 8380492, Chile. Fax: + 56 2 9782912.

E-mail addresses: [aquest@med.uchile.cl](mailto:aquest@med.uchile.cl) (A.F.G. Quest), [slavander@uchile.cl](mailto:slavander@uchile.cl) (S. Lavandero).

<sup>1</sup> These authors contributed equally to this work.

Sphingolipid alterations occur in obesity and metabolic diseases where biological processes such as insulin sensitivity, lipid metabolism, inflammation, and immune responses are deregulated [4]. Particularly, ceramide accumulation has been implicated in the pathogenesis of multiple diseases including diabetes, cardiomyopathies and atherosclerosis [5]. More specifically, in the cardiovascular system, ceramides regulate cardiac contractility, vasomotor responses and endothelial function [6] and they also mediate cardiomyocyte apoptosis triggered by ischemia/reperfusion [7] or by TNF- $\alpha$  [8]. Moreover, C<sub>2</sub>-ceramide stimulates apoptosis in cardiomyocytes by reducing mitochondrial membrane potential ( $\psi_{mt}$ ) and by activation of caspases 8 and 3 [9]. In addition, the anti-apoptotic effect of cardiac preconditioning may be due to reduced ceramide production during sustained ischemia in the rabbit heart [10].

Mitochondria play an important role in apoptotic cell death produced by multiple conditions [11]. C<sub>2</sub>-ceramide alters  $\psi_{mt}$  and promotes cytochrome-c (cyt-c) release and channel formation in the mitochondrial outer membrane [12,13]. In a previous study, we showed that C<sub>2</sub>-ceramide promotes a rapid fragmentation of the mitochondrial network in a concentration- and time-dependent manner and, as a consequence, the early activation of apoptosis [14]. Accordingly, C<sub>2</sub>-ceramide also stimulates mitochondrial network fragmentation in HeLa cells, which was linked to ER Ca<sup>2+</sup> release and cell death [15].

The contribution of Ca<sup>2+</sup> to cell death processes has been extensively described [16,17]. Ca<sup>2+</sup> overload is a common feature of all types of cell

death [17]. Several reports have shown a rise in cytoplasmic  $\text{Ca}^{2+}$  at both early and late stages of the apoptotic process [18].  $\text{Ca}^{2+}$  release from ER and capacitative  $\text{Ca}^{2+}$  influx through  $\text{Ca}^{2+}$  release-activated  $\text{Ca}^{2+}$  channels have also been implicated in apoptosis [15,19,20]. In addition, ceramides cause the release of  $\text{Ca}^{2+}$  from the ER, increasing  $\text{Ca}^{2+}$  in both the cytosol, and the mitochondrial matrix. Accordingly, buffering cytoplasmic  $\text{Ca}^{2+}$  prevents mitochondrial damage and protects HeLa cells from apoptosis [15].

The aim of the current study was to investigate the molecular mechanisms involved in ceramide-dependent cardiomyocyte death and more specifically the role of cytoplasmic  $\text{Ca}^{2+}$  and mitochondria in this process. Our data show that  $\text{C}_2$ -ceramide induces apoptosis and necrosis in cultured cardiomyocytes by increasing cytoplasmic  $\text{Ca}^{2+}$  and promoting loss of mitochondrial function.

## 2. Materials and methods

### 2.1. Reagents

Cell culture reagents, Hanks medium, Dulbecco's modified Eagle's medium (DMEM), M199 medium, pancreatin, gelatin, Triton X-100, 5-bromo-2'-deoxyuridine, gadolinium chloride, propidium iodide (PI), methyl pyruvate (MP), carbonyl cyanide *m*-chlorophenylhydrazone (CCCP), oligomycin, FITC-conjugated anti-IgG mouse antibody and the chemical inhibitors E64D, leupeptin, Z-VAD-fmk, Z-VDAD-fmk and the lactate dehydrogenase (LDH) kit were purchased from Sigma-Aldrich Co (St. Louis, MO). The sphingolipids *D*-erythro-sphingosine-*N*-acetate ( $\text{C}_2$ ) and dihydro-*D*-erythro-sphingosine-*N*-acetate (DH- $\text{C}_2$ ), cyclosporin A (CsA) and HRP-conjugated secondary antibodies anti-IgG rabbit and mouse were from Calbiochem (La Jolla, CA). Antibodies against cytochrome-*c* (cyt-*c*) and anti- $\alpha$ -spectrin were from BD Pharmingen (San Diego, CA) and EMD Millipore (Billerica, MA), respectively. Anti-caspase 3 antibody was purchased in Cell Signaling (Danvers, MA). Fluo 3-AM and tetramethylrhodamine methyl ester (TMRM) were from Invitrogen (Carlsbad, CA). Organic and inorganic compounds, salts, acids and solvents were purchased from Merck (Darmstadt, Germany). CellTiter-Glo Luminescent Cell Viability Assay was purchased from Promega (Madison WI).

### 2.2. Animals

Rats were bred in the Animal Breeding Facility, Faculty of Chemical and Pharmaceutical Sciences, University of Chile (Santiago, Chile). Studies were approved by the Institutional Bioethical Committee, Faculty of Chemical and Pharmaceutical Sciences, University of Chile, in accordance with the National Institutes of Health *Guide for the Care and Use of Laboratory Animals* published by the US (NIH Publication No. 85-23, revised 1996).

### 2.3. Culture of cardiomyocytes

Cardiomyocytes were prepared from hearts of 1- to 3-d-old Sprague-Dawley rats as described previously [21]. Cells were maintained in DMEM/M199 (4:1) medium containing 10% FBS and serum-starved for 24 h prior stimulation. Cells were plated at a density of  $1-8 \times 10^3/\text{mm}^2$  on gelatin-coated 6-, 12-, 24- and 96-wells or 35-mm Petri dishes. For  $\text{Ca}^{2+}$  and immunofluorescence studies, cells were plated on gelatin-coated 25- and 18-mm glass coverslips in 35 mm or 12-well Petri dishes, respectively.

### 2.4. Cell viability and apoptosis assays

The integrity of the plasma membrane was assessed by determining the ability of cells to exclude propidium iodide (PI). The level of PI incorporation was quantified in a FACScan flow cytometer (Becton-Dickinson, San Jose, CA). Cell size was evaluated by forward-angle light scattering

(FSC). PI-negative cells of normal size were considered viable [22,23]. Sub-G1 population was determined in cardiomyocytes permeabilized with methanol and labeled with propidium iodide (PI). Then the cells were analyzed using flow cytometry [22,24].

### 2.5. Mitochondrial membrane potential assay

Mitochondrial membrane potential ( $\psi_{\text{mt}}$ ) was measured as described previously [24]. Briefly, cells were loaded with 200 nM TMRM (used in nonquenching mode) for 30 min at 37 °C. Afterwards, cells were trypsinized and fluorescence was assessed by flow cytometry ( $\lambda_{\text{excitation}} = 543 \text{ nm}$ ;  $\lambda_{\text{emission}} = 560 \text{ nm}$ ) using a FACScan system (Becton-Dickinson, San Jose, CA). CCCP 50  $\mu\text{M}$  for 30 min was used as positive control of mitochondrial depolarization.

### 2.6. Intracellular and mitochondrial $\text{Ca}^{2+}$ measurements

Intracellular and mitochondrial  $\text{Ca}^{2+}$  signals were determined as described previously [25–27]. Images were obtained from cultured cardiomyocytes preloaded with Fluo3-AM or RhodFF using an inverted confocal microscope (Carl Zeiss LSM-5, Pascal 5 Axiovert 200 microscope). Coverslips were mounted in a 1-mL capacity chamber and placed in the microscope for fluorescence measurements after excitation with a laser line of 488-nm for Fluo3-AM or 543-nm for RhodFF. The fluorescent images were collected every 0.4–2.0 s for fast signals and analyzed frame by frame with Image J software (NIH, Bethesda, MD).

### 2.7. Immunofluorescence studies for cytochrome-*c* release

Cyt-*c* release was evaluated by immunofluorescence as described previously [14]. Cardiomyocytes grown on coverslips were fixed with PBS containing 4% paraformaldehyde for 10 min, permeabilized with 0.3% Triton X-100 for 10 min, and blocked for 1 h with 5% BSA in PBS. Cells were then incubated with anti-cyt-*c* antibody at 1:400 and revealed with anti-mouse IgG-Alexa 488. Coverslips were mounted in DakoCytomation fluorescence mounting medium (DakoCytomation, Carpinteria, CA) and visualized by confocal microscope (Carl Zeiss Axiovert 135, LSM Microsystems).

### 2.8. Intracellular ATP levels

Cellular ATP content was measured using the luciferin/luciferase based ATP detection kit CellTiter-Glo Luminescent Cell Viability Assay (Promega) following the manufacturer's instructions. Briefly, cardiomyocytes were cultured in 96-well Petri dishes and washed 3 times with PBS before incubation with the reagent. Sample luminescence was quantified in a TopCount NXT microplate luminescence counter (Perkin-Elmer, Waltham, MA). Data was normalized as fold over control.

### 2.9. Western blot analysis

Equal amounts of protein from cells were separated by SDS-PAGE (10% polyacrylamide gels) and electrotransferred to nitrocellulose. Membranes were blocked with 5% milk in Tris-buffered saline, pH 7.6, containing 0.1% (v/v) Tween 20 (TBST). Membranes were incubated with primary antibodies at 4 °C and re-blotted with horseradish peroxidase-linked secondary antibody [1:5000 in 1%(w/v) milk in TBST]. The bands were detected using ECL reagent followed by exposure to Kodak film and then quantified by scanning densitometry. Proteins were normalized to  $\beta$ -tubulin levels.

### 2.10. LDH release assay

Necrosis was measured by quantifying LDH activity in culture medium. LDH activity was determined by measuring the decrease

in NADH (10 mg/mL) spectrophotometrically at 340 nm for 2 min, in the presence of lactate (2.5 mg/mL). The fraction of LDH released was determined by comparing LDH activity in the culture medium relative to total LDH activity.

### 2.11. Cardiomyocyte transfection

Small interfering RNAs (siRNA) for calpains I and II and negative control (Mission, Sigma-Aldrich Corp., St Louis, MO) were used following the manufacturer's instructions. Cells were grown and after 48 h, transfected with siRNAs at a concentration of 25 nM with Lipofectamine™ RNAiMAX (Invitrogen, Carlsbad, CA). After 6 h incubation in Opti-mem®, the medium was removed and replaced with 10% FBS in DMEM/M199. Calpain I/II down-regulation was assessed 48 h post-transfection. The siRNAs used for knockdown experiments were as follows:

- Negative control, catalog number SIC001;
- Calpain Ia, sense (5'-GUUGUGACCUUUGAUCUAU-3'), antisense (5'-AUAGAUCAAAGGUCACAAC-3')
- Calpain Ib, sense (5'-CUGACUAUGUUUGCAUGAA-3'), antisense (5'-UUCAUGCAAACAUAGUCAG-3')
- Calpain IIa, sense (5'-GAACGUACGGGAACAUUUA-3'), antisense (5'-UAAAUGUCCCGUACGUUC-3')
- Calpain IIb, sense (5'-GUUUCAAGCUGCCUGUCA-3'), antisense (5'-UGACAGGGCAGCUUGAAAC-3')

Different combinations of two siRNAs against each calpain were tested, obtaining the best results with the siRNA mixture containing the specific siRNAs Ia and IIa, which was used for all the subsequent experiments (Supplementary Fig. 1A).

### 2.12. RNA purification and real-time reverse transcription-PCR (RT-PCR)

Total RNA was isolated using TRIzol according to the manufacturer's protocol (Invitrogen, Carlsbad, CA). Random hexamers were used for reverse-transcription reactions using superscript II (Invitrogen, Carlsbad, CA). RT-PCR was performed using SYBR green (Invitrogen, Carlsbad, CA). Data for each transcript were normalized to both GAPDH and 18S rRNA as internal controls using the 2- $\Delta\Delta$ Ct method. The primers used are listed below:

Calpain 1 Rat Forward 5'-TGGAGATCAGTGTCAAGGAGTTAC-3'  
 Calpain 1 Rat Reverse 5'-GCACTCATGCTGCCAGACTGTCCAGGTCA-3'  
 Calpain 2 Rat Forward 5'-GGGCAGACCAACATCCACCTCAGCAAAAAC-3'  
 Calpain 2 Rat Reverse 5'-ATCTCCGCATCTCTCCAGCCAGC-3'

### 2.13. Expression of results and statistical analysis

Data are presented either as means  $\pm$  SD of a number (n) of independent experiments or as examples of representative experiments performed on at least three separate occasions. Data were analyzed by analysis of variance and comparisons between groups were performed using a protected Tukey *t*-test. A value of  $p < 0.05$  was chosen as the limit of statistical significance.

## 3. Results

### 3.1. C<sub>2</sub>-ceramide induces apoptosis and necrosis in cardiomyocytes

Currently, there are conflicting views concerning the role of ceramides as second messengers in several cardiac pathologies [28]. One possibility to explain the death-promoting functions of ceramides invokes damage to mitochondria and alterations in calcium homeostasis. Whether such mechanisms may be relevant in cardiomyocytes remained to be determined. Thus, we investigated the types of cell death induced by C<sub>2</sub>-ceramide in cultured rat cardiomyocytes and the role of Ca<sup>2+</sup>


and mitochondria in these events. For these experiments, we used a serum-free culture model to enhance sensitivity and detect more readily the cell death induced by C<sub>2</sub>-ceramide than previously described [14]. As shown in Fig. 1A the treatment of cardiomyocytes with C<sub>2</sub>-ceramide 20  $\mu$ M during a 6 h period induces a significant increase in the sub G1 population (from 8.0%  $\pm$  1.6 to 24.2%  $\pm$  2.0), indicative of apoptosis, which however does not account for the total cell death observed under these conditions, as evaluated by PI incorporation (from 7.8%  $\pm$  0.9 to 41.4%  $\pm$  5.1). Importantly, this effect was not observed when the cells were treated with the inactive analog, dihydro-C<sub>2</sub>-ceramide, discarding a detergent effect of these short-chain lipids. The same treatment with C<sub>2</sub>-ceramide also stimulated LDH release, as determined by measuring the activity of this enzyme in the culture medium (from 10.0%  $\pm$  0.5 to 33.3%  $\pm$  6.8), as well as a decrease in the  $\psi$ mt and the intracellular levels of ATP (–26.8%  $\pm$  3.4 and –30.3%  $\pm$  2.3, using CCCP 50  $\mu$ M or oligomycin 2  $\mu$ M as negative and positive controls, respectively) (Fig. 1B–D). Moreover, the treatment of cardiomyocytes with C<sub>2</sub>-ceramide also induced substantial release of cyt-c after 1–3 h of treatment. This effect decreased upon exposure to C<sub>2</sub>-ceramide for longer periods of time (Fig. 1E). Collectively, these results suggest that the treatment of cardiomyocytes with C<sub>2</sub>-ceramide induces cell death by a mechanism that involved time-dependent early apoptosis followed by a delayed necrosis.

### 3.2. Ca<sup>2+</sup> influx triggered by C<sub>2</sub>-ceramide stimulates cardiomyocyte death

Ceramide-induced cell death has often been associated with increments in the levels of two intracellular second messengers, Ca<sup>2+</sup> and ROS [29–31]. To study the role of both messengers, two different approaches were used. ROS were measured by electron spin resonance (ESR) using the spin trap DMPO, whereas Ca<sup>2+</sup> influx was assayed by confocal microscopy using the fluorescent probe Fluo 3-AM. C<sub>2</sub>-ceramide (20  $\mu$ M) did not change the intracellular levels of ROS in cultured cardiomyocytes (Fig. 2A). Moreover the presence of antioxidants, including N-acetyl cysteine (NAC), Trolox (a water-soluble derivative of vitamin E) and Tiron did not reduce the C<sub>2</sub>-ceramide-induced cell death (Fig. 2B). On the other hand, ceramide increased cytoplasmic Ca<sup>2+</sup> levels in a manner that was dependent on the presence of external Ca<sup>2+</sup> (Fig. 3A). To investigate whether this Ca<sup>2+</sup> signal contributes to cell death triggered by ceramide, cardiomyocytes were pretreated either with the Ca<sup>2+</sup> chelating agent EGTA (2 mM) or with GdCl<sub>3</sub> (10  $\mu$ M), a potent but nonselective antagonist of nonselective cation currents [32]. Both agents decreased PI incorporation into the cells after treatment with C<sub>2</sub>-ceramide and also prevented decreases in  $\psi$ mt and intracellular ATP levels (Fig. 3B–D), whereby Gd<sup>3+</sup> was much more effective than EGTA. Additionally, both EGTA and Gd<sup>3+</sup> delayed cyt-c redistribution, which under these conditions was no more longer significant at 3 h of treatment (Fig. 3E).

### 3.3. Calpains but not caspases are involved in cardiomyocyte death induced by C<sub>2</sub>-ceramide

To shed light on mechanisms underlying cell death induced by C<sub>2</sub>-ceramide, activation of two important downstream effectors and key cell death mediators was evaluated in cardiomyocytes, namely the cysteine protease caspases and Ca<sup>2+</sup>-dependent calpains [33]. The activation of these proteases was evaluated by determining the cleavage of pro-caspase 3 to active caspase-3 and of  $\alpha$ -spectrin, an important target of activated calpains [34]. As shown in the Supplementary Fig. 1B–C, under our experimental conditions only  $\alpha$ -spectrin cleavage was detected, suggesting that calpains are activated in our experimental model. Moreover, the inhibitors of caspases Z-VDAD-fmk (50  $\mu$ M) or Z-VAD-fmk (50  $\mu$ M) did not prevent cell death induced by C<sub>2</sub>-ceramide, whereas the calpain inhibitors leupeptin (100  $\mu$ M) or E64D (10  $\mu$ M) did (Fig. 4A–B). Interestingly, leupeptin also attenuated




**Fig. 1.** C<sub>2</sub>-ceramide induces apoptosis and necrosis in cultured cardiomyocytes. (A) Cells were treated with C<sub>2</sub>-ceramide (C<sub>2</sub>, 20 μM) or the inactive analog dihydroceramide (DH-C<sub>2</sub>) at the same concentration. After 6 h, PI incorporation and the subG1 population were quantified by FACS analysis. Values are shown as the mean ± SD of 3 independent experiments, \*\*\*P < 0.001. (B) Cells were incubated with C<sub>2</sub>-ceramide or DH-C<sub>2</sub> (20 μM for 6 h) and necrosis was determined by the extent of LDH release to the culture medium. Data represent means ± SD (n = 3), \*\*\*\*P < 0.001 vs. Control (Co). (C–D) Quantification of the mitochondrial membrane potential (ψ<sub>mt</sub>) and the intracellular levels of ATP in cells treated with C<sub>2</sub>-ceramide or DH-C<sub>2</sub> (20 μM, 6 h). Values are means ± SD of n = 5 and 6 experiments, respectively, \*P < 0.05, \*P < 0.005 and \*\*\*\*P < 0.001 vs. Co. (E) Cells were incubated with C<sub>2</sub>-ceramide (C<sub>2</sub>, 20 μM) or DH-C<sub>2</sub> for the indicated period of time and cytochrome-c was detected by indirect immunofluorescence analysis. Cytochrome-c redistribution was quantified by counting the cells with a diffuse pattern of fluorescence. (n = 7), \*\*P < 0.01, \*\*\*P < 0.001 vs. control and ##P < 0.01 vs. C<sub>2</sub>-ceramide (C<sub>2</sub>) 3 h.

the decrease in the intracellular levels of ATP induced by C<sub>2</sub>-ceramide. However, neither E64D nor leupeptin prevented the decrease in ψ<sub>mt</sub> in cells exposed to C<sub>2</sub>-ceramide (Supplementary Fig. 2).

Given that some calpain inhibitors are rather non-specific [35] and that calpains I and II (also known as μ-calpain and m-calpain, respectively) are both expressed in the heart requiring high Ca<sup>2+</sup> concentration to be activated [36], both calpain isoforms were knocked

down using siRNA technology. Fig. 4C shows that siRNAs against calpains I and II prevented the cell death induced by C<sub>2</sub>-ceramide. These results were similar to those obtained by the use of calpain inhibitors. Also, this strategy did not revert the decrease in the ψ<sub>mt</sub> and the intracellular levels of ATP (Fig. 4D–E). Altogether, these results suggest that mitochondrial dysfunction occurs prior to the onset of the calpain-dependent cell death induced by ceramides.




**Fig. 2.** Ceramide does not stimulate ROS generation in cardiomyocytes. (A) Cells were incubated with  $C_2$ -ceramide ( $C_2$ , 20  $\mu$ M) for a 6 h period in the presence of DMPO (200 mM) for 30 min. Cells were lysed and extracts were analyzed by electron spin resonance (ESR). Spectrometer conditions: microwave frequency 9.83 GHz, microwave power 20 mW, modulation amplitude 0.2 G, scan rate 1.25 G/s, time constant 0.5 s, and number of scans: 20. Plots are representative of 3 independent experiments ( $n = 3$ ). (B) Effect of the antioxidant agents N-acetylcysteine (NAC, 5 mM), Trolox (5 mM) and Tiron (5 mM) on PI incorporation in cardiomyocytes treated with  $C_2$  ceramide ( $C_2$ , 20  $\mu$ M) for 6 h. ( $n = 3$ ), \*\*\* $P < 0.001$  vs. control (Co).

#### 3.4. $C_2$ -ceramide induces cardiomyocyte death by modulating mitochondrial function

We have previously shown that  $C_2$ -ceramide induced fragmentation of the mitochondrial network in cultured rat cardiomyocytes. For this reason, we evaluated here whether mitochondrial fission was triggered under our experimental conditions and whether this process was also regulated by the  $Ca^{+2}$  influx. Following the treatment for 6 h with


$C_2$ -ceramide (20  $\mu$ M) in serum-free medium, substantial mitochondrial network fragmentation was detected (Fig. 5A–B), as evidenced by an increase in the number of mitochondria per cell and a decrease in mean mitochondrial volume, both considered as criteria to document mitochondrial fission [14,37,38]. Moreover, this mitochondrial fragmentation process was prevented by the pre-incubation of cardiomyocytes with EGTA and  $Gd^{+3}$  (Fig. 5A–B), thereby connecting our previous results (Fig. 3) with the onset of mitochondrial dysfunction.



**Fig. 3.**  $\text{Ca}^{2+}$  influx induced by  $\text{C}_2$ -ceramide modulates cardiomyocyte death. (A) Changes in internal cytosolic  $\text{Ca}^{2+}$  were investigated in individual, fluo3-AM-loaded cells maintained in medium with or without  $\text{Ca}^{2+}$ . Cells were stimulated with  $\text{C}_2$ -ceramide ( $\text{C}_2$ , 20  $\mu\text{M}$ ) or the control (DMSO vehicle) for the time indicated by the arrow. Results are expressed as relative total fluorescence [ratio of fluorescence difference ( $F - F_0$ ), to basal value ( $F_0$ )]  $\times 100$  as a function of time and are representative of 5 independent experiments in which at least 20 cells were analyzed in each case. The effect of the chelating agent EGTA (1 mM) and  $\text{Gd}^{+3}$  (10  $\mu\text{M}$ ) were studied in cells treated with  $\text{C}_2$ -ceramide ( $\text{C}_2$ , 20  $\mu\text{M}$ ) for 6 h on (B) PI incorporation,  $n = 3$ ; (C) mitochondrial potential,  $n = 5$ ; and (D) intracellular levels of ATP,  $n = 7$ ,  $^*P < 0.05$  vs. Control (Co) and  $^{\#}P < 0.05$  vs.  $\text{C}_2$  6 h. (E) Effect of EGTA (1 mM) and  $\text{Gd}^{+3}$  (10  $\mu\text{M}$ ) pre-incubation on the redistribution of cytochrome-c in cells treated with  $\text{C}_2$ -ceramide ( $\text{C}_2$ , 20  $\mu\text{M}$ ),  $n = 7$ ,  $^{**}P < 0.01$ ,  $^{***}P < 0.001$  vs. Control (Co),  $^{\#}P < 0.05$  and  $^{###}P < 0.001$  vs.  $\text{C}_2$  3 h.

Although the relationship between mitochondrial fission and apoptosis is still controversial [39,40], our previous data [14] established a model whereby loss of  $\psi_{\text{mt}}$  precedes mitochondrial fission, which is

then followed by the release of cyt-c. These results suggested that ceramide-induced mitochondrial fission is required to trigger apoptosis. Moreover, the pre-incubation of cardiomyocytes with cyclosporine A



**Fig. 4.** Calpains but not caspases are involved in cardiomyocyte death induced by C<sub>2</sub>-ceramide. PI incorporation analysis in cells treated with C<sub>2</sub>-ceramide (C<sub>2</sub>, 20 μM) for 6 h and pre-incubated (30 min) with (A) the caspase 2 (Z-VDAD-fmk) and pan-caspase (Z-VAD-fmk) inhibitors (50 μM), n = 3 or (B) the calpain inhibitors leupeptin (Leu, 100 μM) and E64D (10 μM), n = 5, \*\*\*P < 0.001 vs. Control (Co) and #P < 0.05 vs. C<sub>2</sub> 6 h. Effect of the calpain I and II knockdown (siCalpI/II) in cells treated with C<sub>2</sub>-ceramide (C<sub>2</sub>, 20 μM 6 h) on the (C) PI incorporation, n = 3; (D) mitochondrial potential, n = 3; and (E) intracellular levels of ATP, n = 3. \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001 vs. a negative siRNA Control (siCo) and ##P < 0.01 vs. siCo C<sub>2</sub> 6 h.

(250 nM), an inhibitor of the mitochondrial transition pore, a key step in the development of mitochondrial dependent cell death, almost completely suppressed C<sub>2</sub>-ceramide-enhanced PI incorporation, as well as decreased  $\psi_{mt}$  and intracellular ATP levels (Fig. 5C–E).

Subsequently, we sought to establish a direct relationship between the increase in cytosolic Ca<sup>2+</sup> influx observed in cardiomyocytes treated with C<sub>2</sub>-ceramide and decreased mitochondrial Ca<sup>2+</sup> buffer capacity, which was previously described for fragmented mitochondria [41,42]. To that end, we loaded the cells with the mitochondrial Ca<sup>2+</sup> dye Rhod-FF and then added histamine, a classical agent that evokes a Ins(3,4,5)P<sub>3</sub>-dependent Ca<sup>2+</sup> release from the ER [43]. As shown in Fig. 5F, histamine-stimulated mitochondrial Ca<sup>2+</sup> uptake was significantly lower in ceramide-pretreated cardiomyocytes than controls. These results suggest that fragmented mitochondria in C<sub>2</sub>-ceramide-treated cells display decreased ER-mitochondria coupling. Moreover, these observations are indicative of reduced Ca<sup>2+</sup> buffering capacity that may explain the increase in the cytosolic Ca<sup>2+</sup> and subsequent activation of calpains as effectors of cell death.

Finally, it is well known that mitochondrial Ca<sup>2+</sup> uptake stimulates mitochondrial metabolism, in terms of mitochondrial respiration and ATP production because the activities of dehydrogenases in the Krebs cycle are stimulated by Ca<sup>2+</sup> either directly (isocitrate and  $\alpha$ -ketoglutarate dehydrogenases) or indirectly (pyruvate dehydrogenase) [44]. If C<sub>2</sub>-ceramide causes mitochondrial fragmentation and as a consequence affects mitochondrial Ca<sup>2+</sup> uptake and metabolism, we hypothesized that stimulating mitochondrial metabolism should decrease ceramide-induced cell death, by precluding decreased  $\psi_{mt}$  and ATP levels. To test this idea, we sought to bypass the requirement for mitochondrial Ca<sup>2+</sup> by enhancing the availability of TCA cycle intermediates and increasing the production of reducing equivalents. To this end, cells were pre-incubated with membrane-permeable methyl-pyruvate (MP) that is oxidized to provide reducing equivalents (NADH), which then drive oxidative phosphorylation and ATP production [45]. Fig. 6A–C shows that MP partially prevented ceramide-


induced cardiomyocyte death, as assessed by PI incorporation, the decrease in the  $\psi_{mt}$  as well as the decrease in the intracellular levels of ATP.

#### 4. Discussion

Our data summarized in the graphical abstract strongly suggest that C<sub>2</sub>-ceramide induces cardiomyocyte death through a molecular mechanism involving enhanced Ca<sup>2+</sup> influx, increased mitochondrial fragmentation and a reduction in the mitochondrial Ca<sup>2+</sup> buffer capacity. These changes lead to an increase in cytosolic Ca<sup>2+</sup> levels, which is depicted here as responsible for the activation of calpains. Interestingly, some of these effects were partially overcome by medium supplementation with membrane-permeable methyl-pyruvate. Our data also show that C<sub>2</sub>-ceramide induces both early apoptosis and delayed necrosis. The former is dependent on Ca<sup>2+</sup> influx (Fig. 3E) and thus can be blocked by preventing either the rise in cytoplasmic Ca<sup>2+</sup> or loss of mitochondrial function and both approaches protect cardiomyocytes against ceramide-induced cell death.

##### 4.1. Ceramide-induced cardiomyocyte death

A considerable body of evidence implicates ceramides in apoptotic cardiomyocyte death [28]. However, several recent reports in other cell types suggest that cell death with necrotic features may occur due to increased endogenous ceramide levels, as well as in response to treatment with cell-permeable ceramides [46–50]. In this study, we sought to define the molecular mechanisms by which cell-permeable ceramides promote cardiomyocyte death. Our current study relies heavily on the use of a flow cytometry assay that identifies different cell populations on the basis of fluorescence intensity due to DNA staining by PI that enters the cell as a consequence of augmented membrane permeability [3,46]. In order to evaluate whether cardiomyocyte membrane permeability to PI triggered by exposure to cell-permeable C<sub>2</sub>-ceramide correlated with release of



**Fig. 5.** C<sub>2</sub>-ceramide induces cardiomyocyte death by modulating mitochondrial function. (A) Mitochondrial fragmentation induced by C<sub>2</sub>-ceramide (C<sub>2</sub>, 20 μM) was studied in cardiomyocytes pre-incubated (30 min) with or without EGTA (1 mM) and Gd<sup>3+</sup> (10 μM). Cells were incubated with C<sub>2</sub>-ceramide for 6 h and then loaded with mitotracker green. Multi-slice imaging reconstitution was obtained by confocal microscopy to show mitochondrial morphology. The scale bar is 20 μm. (B) The mean mitochondrial volume and the number of mitochondria per cell were determined. Values shown are mean ± SD, n = 4, \*\*\*P < 0.001 vs. Control (Co) and ###P < 0.001 vs. C<sub>2</sub> 6 h. The effect of the mitochondrial transition pore inhibitor, cyclosporine (CsA, 250 nM) was studied in cells treated with C<sub>2</sub>-ceramide (C<sub>2</sub>, 20 μM) for 6 h on (C) PI incorporation, n = 3; (D) mitochondrial potential, n = 4 and; (E) intracellular levels of ATP, n = 5. \*\*P < 0.01, \*\*\*P < 0.001 vs. Control (Co), #P < 0.05, ##P < 0.01 and ###P < 0.001 vs. C<sub>2</sub> 6 h. (F) Representative traces of mitochondrial calcium ([Ca<sup>2+</sup>]<sub>mt</sub>) obtained from cardiomyocytes loaded with the Rhod-FF calcium probe, either untreated (Control) or treated with C<sub>2</sub>-ceramide (C<sub>2</sub>, 20 μM) for 6 h prior to histamine addition, which is indicated by an arrow. The mitochondrial uncoupler CCCP (50 μM) was used as a control. Results are expressed as relative total fluorescence [ratio of fluorescence difference (F – F<sub>0</sub>), to basal value (F<sub>0</sub>)] × 100 over time and are representative of 3 independent experiments in which at least 10 cells were analyzed in each case.


cytoplasmic content from cells, LDH release, a criterion employed to identify necrotic cell death, was used in parallel. Unexpectedly as shown in Fig. 1, 6 h of treatment with C<sub>2</sub>-ceramide induced both early apoptosis and delayed necrosis. Whereas necrosis was only detected by LDH release after 6 h treatment, early apoptotic markers, such as cyt-c re-distribution were detected earlier (3 h). Ceramide-induced cell death was apparently Ca<sup>2+</sup>-dependent (Fig. 2E) and cyt-c redistribution was delayed upon addition of either EGTA or Gd<sup>3+</sup>. Consequently, we only observed decreases in ATP after 6 h of ceramide treatment, correlating with the increased LDH release, which is in agreement with the general perception that apoptosis requires ATP while necrosis occurs

in its absence. Moreover, in contrast to those models where primary necrosis occurs, secondary necrosis usually follows apoptosis if the removal of apoptotic bodies is delayed or absent, as is the case of cell culture models [51]. In these cases, necrotic events, such as LDH release, occur coincident with or after cyt-c release [52], observations that strongly correlate with the results described in the present study.

#### 4.2. Ceramide, second messengers and executors of cell death

It has been shown that ceramides increase cytoplasmic Ca<sup>2+</sup> concentrations in different types of cells. Indeed, cytoplasmic Ca<sup>2+</sup> levels





**Fig. 6.** Improved mitochondrial function prevents cardiomyocyte death induced by C<sub>2</sub>-ceramide. Effects of methyl-pyruvate (5 mM) in cells treated with C<sub>2</sub>-ceramide (C<sub>2</sub>, 20 μM) 6 h on (A) PI Incorporation, n = 5; (B) mitochondrial potential, n = 5 and; (C) intracellular levels of ATP, n = 7. \*P < 0.05, \*\*\*P < 0.001 vs. Control (Co) and #P < 0.05, ##P < 0.01 and ###P < 0.001 vs. C<sub>2</sub> 6 h.

are increased in cardiomyocytes exposed to C<sub>2</sub>-ceramide (Fig. 3A). In addition to ATP-dependent Ca<sup>2+</sup> influx, ceramide increases Ca<sup>2+</sup> from a thapsigargin-sensitive Ca<sup>2+</sup> pool and triggers a subsequent capacitative Ca<sup>2+</sup> entry in Jurkat T cells [53]. In the aforementioned studies, increased cytoplasmic Ca<sup>2+</sup> concentrations were linked to the liberation of Ca<sup>2+</sup> from intracellular stores and the activation of a store-operated Ca<sup>2+</sup> channel [53]. Similarly, in our study ceramide increased cytoplasmic Ca<sup>2+</sup> was necessary for the subsequent cardiomyocyte death because both, EGTA and Gd<sup>3+</sup> decreased PI incorporation and also prevented the deleterious effects of ceramide on ψ<sub>mt</sub> and intracellular ATP levels (Fig. 3C–D). Activation of calpains due to increased intracellular Ca<sup>2+</sup> concentrations has been linked to cardiomyocyte death [54]. Our data agree with these observations because two different calpain inhibitors (leupeptin and E64D) and siRNAs for these proteases prevented the ceramide-induced cardiomyocyte death. However, they did not exert the same inhibitory effect on ψ<sub>mt</sub> and the intracellular levels of ATP (Fig. 4). These results suggest that calpain activation represents an event that occurs downstream of mitochondrial dysfunction during cardiomyocyte death. Interestingly, caspases seem not to be involved in cardiomyocyte death induced by C<sub>2</sub>-ceramide (Fig. 4A). These results are in agreement with studies in neuroblastoma cells where synthetic ceramides induced a caspase-independent, necrosis-like morphology [55]. Moreover, ceramides kill normal lymphocytes and lymphoid cell lines in the absence of caspase activation, triggering a nonapoptotic

morphology in dying cells [47]. Thus, ceramide-induced cell death is apparently not regulated by caspase activation, although the type of death triggered by these lipids is strongly dependent on the cell type and context.

#### 4.3. Ceramide, mitochondrial morphology and function

Different studies have shown that ceramides alter the homeostasis of several organelles, including particularly mitochondria [56]. According to this evidence, C<sub>2</sub>- and C<sub>16</sub>-ceramides form channels in planar lipid bilayers allowing the release of cyt-c [56]. On the other hand, C<sub>2</sub>-ceramide also decreases ψ<sub>mt</sub> in isolated heart mitochondria [57]. Our previous study established that C<sub>2</sub>-ceramide regulates mitochondrial dynamics through the stimulation of mitochondrial fission, involved among other events in the activation of cardiomyocyte apoptosis [14]. This fission process was accompanied by early translocation of the fission protein Drp-1 to the mitochondria [14]. However, the mechanisms that trigger this process remained unknown.

In the present study, we show that C<sub>2</sub>-ceramide not only induces mitochondrial fission, but also decreases ψ<sub>mt</sub> and the intracellular levels of ATP (Fig. 5A–E). Also, histamine-induced mitochondrial Ca<sup>2+</sup> uptake in cardiomyocytes is reduced (Fig. 5F), suggesting that the fragmented mitochondria observed in ceramide-treated cells display a lower Ca<sup>2+</sup> buffering capacity. Moreover, this may explain the increase in cytosolic Ca<sup>2+</sup> observed following C<sub>2</sub>-ceramide treatment and the subsequent activation of calpains as effectors of cell death. These data agree with previous reports establishing that a fragmented mitochondrial network affects mitochondrial Ca<sup>2+</sup> buffering capacity and the spatial and temporal development of cytoplasmic Ca<sup>2+</sup> signals [41]. Increases in cytosolic Ca<sup>2+</sup> trigger the translocation of the protein Drp1 to the mitochondria, thereby unleashing mitochondrial fragmentation [58]. In our graphical abstract we propose a model where C<sub>2</sub>-ceramide induces an increase in cytosolic Ca<sup>2+</sup>, which triggers mitochondrial network fragmentation and a decrease in the function of this organelle. In this scenario, mitochondrial fragmentation reduces the mitochondrial Ca<sup>2+</sup> buffering capacity, increases cytosolic Ca<sup>2+</sup> levels and activates calpains.

Finally, one of the most interesting findings of this study was the ability of MP to partially prevent the decrease in mitochondrial metabolism and preclude cardiomyocyte death (Fig. 6). Constitutive InsP<sub>3</sub>R-dependent Ca<sup>2+</sup> release to mitochondria is an essential event required for efficient mitochondrial respiration and the maintenance of normal cell bioenergetics [45,59]. This process seems to be altered in cardiomyocytes treated with exogenous ceramides, given that histamine stimulation results in reduced mitochondrial Ca<sup>2+</sup> uptake following ceramide treatment. Future work should clarify whether metabolic rescue by MP prevents the reduction in mitochondrial Ca<sup>2+</sup> buffering capacity and also whether this may represent a beneficial approach to treat other pathological states where ceramides are implicated.

#### 4.4. Concluding remarks

Our data provide novel evidence that cardiomyocyte mitochondria are primary targets of cell-permeable ceramides. These sphingolipids promote cytosolic Ca<sup>2+</sup> influx, mitochondrial fragmentation and dysfunction, as well as cell death through apoptosis and necrosis. Our results also show that mitochondrial dysfunction following C<sub>2</sub>-ceramide-induced mitochondrial ψ<sub>mt</sub> and ATP decrease is a major driving force for cardiomyocyte apoptosis. Thus, metabolic rescue observed upon addition of MP may represent an appropriate strategy to avoid cardiomyocyte death in a broad range of cardiac pathologies where ceramides and calpain activation may play a major role, such as in ischemia-reperfusion [36,60] and doxorubicin treatment [61,62].

Supplementary data to this article can be found online at <http://dx.doi.org/10.1016/j.bbadis.2013.04.009>.

## Disclosure statement

No potential conflicts of interest are reported for any of the authors.

## Acknowledgements

This work was supported by CONICYT (grant Anillo ACT 1111 and FONDAP 1501006 to A.F.G.Q. and S.L.) and Red 120003 (to S.L. and A.F.G.Q.), the National Institutes of Health (HL097768 and HL072016 to B.A.R.) and the American Heart Association (06552024 to B.A.R.). We are thankful for the PhD fellowships from CONICYT, Chile to V.P., J.K. and N.T., as well as for the FONDECYT postdoctoral funding 3110114 to R.T. V.P. holds a Postdoctoral International fellowship from Bicentennial Program, CONICYT, CHILE. We finally thank Fidel Albornoz for his excellent technical assistance.

## References

- [1] S.T. Pruet, A. Bushnev, K. Hagedorn, M. Adiga, C.A. Haynes, M.C. Sullards, D.C. Liotta, A.H. Merrill, Biodiversity of sphingoid bases ("sphingosines") and related amino alcohols, *J. Lipid Res.* 49 (2008) 1621–1639.
- [2] Y.A. Hannun, L.M. Obeid, The ceramide-centric universe of lipid-mediated cell regulation: stress encounters of the lipid kind, *J. Biol. Chem.* 277 (2002) 25847–25850.
- [3] J. Villena, M. Henriquez, V. Torres, F. Moraga, J. Díaz-Elizondo, C. Arredondo, M. Chiong, C. Olea-Azar, A. Stutzin, S. Lavandero, A.F.G. Quest, Ceramide-induced formation of ROS and ATP depletion trigger necrosis in lymphoid cells, *Free Radic. Biol. Med.* 44 (2008) 1146–1160.
- [4] T. Hla, A.J. Dannenberg, Sphingolipid signaling in metabolic disorders, *Cell Metab.* 16 (2012) 420–434.
- [5] W.L. Holland, S.A. Summers, Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism, *Endocr. Rev.* 29 (2008) 381–402.
- [6] X. Li, K.A. Becker, Y. Zhang, Ceramide in redox signaling and cardiovascular diseases, *Cell. Physiol. Biochem.* 26 (2010) 41–48.
- [7] A.E. Bielawska, J.P. Shapiro, L. Jiang, H.S. Melkonyan, C. Piot, C.L. Wolfe, L.D. Tomei, Y.A. Hannun, S.R. Umansky, Ceramide is involved in triggering of cardiomyocyte apoptosis induced by ischemia and reperfusion, *Am. J. Pathol.* 151 (1997) 1257–1263.
- [8] K.A. Crown, M.T. Page, C. Nguyen, D. Zechner, V. Gutierrez, K.L. Comstock, C.C. Glembotski, P.J. Quintana, R.A. Sabbadini, Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes Involvement of the sphingolipid signaling cascade in cardiac cell death, *J. Clin. Invest.* 98 (1996) 2854–2865.
- [9] J.Y. Kong, S.S. Klassen, S.W. Rabkin, Ceramide activates a mitochondrial p38 mitogen-activated protein kinase: a potential mechanism for loss of mitochondrial transmembrane potential and apoptosis, *Mol. Cell. Biochem.* 278 (2005) 39–51.
- [10] L. Argaud, A.-F. Prigent, L. Chalabreysse, J. Loufouat, M. Lagarde, M. Ovize, Ceramide in the antiapoptotic effect of ischemic preconditioning, *Am. J. Physiol. Heart Circ. Physiol.* 286 (2004) H246–51.
- [11] C. Garrido, L. Galluzzi, M. Brunet, P.E. Puig, C. Didelot, G. Kroemer, Mechanisms of cytochrome c release from mitochondria, *Cell Death Differ.* 13 (2006) 1423–1433.
- [12] L.J. Siskind, R.N. Kolesnick, M. Colombini, Ceramide forms channels in mitochondrial outer membranes at physiologically relevant concentrations, *Mitochondrion* 6 (2006) 118–125.
- [13] B. Tomassini, R. Testi, Mitochondria as sensors of sphingolipids, *Biochimie* 84 (2002) 123–129.
- [14] V. Parra, V. Eisner, M. Chiong, A. Criollo, F. Moraga, A. Garcia, S. Härtel, E. Jaimovich, A. Zorzano, C. Hidalgo, S. Lavandero, Changes in mitochondrial dynamics during ceramide-induced cardiomyocyte early apoptosis, *Cardiovasc. Res.* 77 (2008) 387–397.
- [15] P. Pinton, D. Ferrari, E. Rapizzi, F. Di Virgilio, T. Pozzan, R. Rizzuto, The Ca<sup>2+</sup> concentration of the endoplasmic reticulum is a key determinant of ceramide-induced apoptosis: significance for the molecular mechanism of Bcl-2 action, *EMBO J.* 20 (2001) 2690–2701.
- [16] C.W. Distelhorst, G.C. Shore, Bcl-2 and calcium: controversy beneath the surface, *Oncogene* 23 (2004) 2875–2880.
- [17] C.J. Hanson, M.D. Bootman, H.L. Roderick, Cell signalling: IP<sub>3</sub> receptors channel calcium into cell death, *Curr. Biol.* 14 (2004) R933–5.
- [18] C.W. Distelhorst, M.D. Bootman, Bcl-2 interaction with the inositol 1,4,5-trisphosphate receptor: role in Ca<sup>2+</sup> signaling and disease, *Cell Calcium* 50 (2011) 234–241.
- [19] S. Jiang, S.C. Chow, P. Nicotera, S. Orrenius, Intracellular Ca<sup>2+</sup> signals activate apoptosis in thymocytes: studies using the Ca(2+)-ATPase inhibitor thapsigargin, *Exp. Cell Res.* 212 (1994) 84–92.
- [20] I.E. Wertz, V.M. Dixit, Characterization of calcium release-activated apoptosis of LNCaP prostate cancer cells, *J. Biol. Chem.* 275 (2000) 11470–11477.
- [21] R. Foncea, M. Andersson, A. Ketterman, V. Blakesley, M. Sapag-Hagar, P.H. Sugden, D. LeRoith, S. Lavandero, Insulin-like growth factor-I rapidly activates multiple signal transduction pathways in cultured rat cardiac myocytes, *J. Biol. Chem.* 272 (1997) 19115–19124.
- [22] P. Marambio, B. Toro, C. Sanhueza, R. Troncoso, V. Parra, H. Verdejo, L. García, C. Quiroga, D. Munafo, J. Díaz-Elizondo, R. Bravo, M.-J. González, G. Díaz-Araya, Z. Pedrozo, M. Chiong, M.I. Colombo, S. Lavandero, Glucose deprivation causes oxidative stress and stimulates aggresome formation and autophagy in cultured cardiac myocytes, *Biochim. Biophys. Acta* 1802 (2010) 509–518.
- [23] R. Troncoso, J.M. Vicencio, V. Parra, A. Nemchenko, Y. Kawashima, A. del Campo, B. Toro, P.K. Battiprolu, P. Aranguiz, M. Chiong, S. Yakar, T.G. Gillette, J.A. Hill, E.D. Abel, D. LeRoith, S. Lavandero, Energy-preserving effects of IGF-1 antagonize starvation-induced cardiac autophagy, *Cardiovasc. Res.* 93 (2012) 320–329.
- [24] J.P. Munoz, M. Chiong, L. García, R. Troncoso, B. Toro, Z. Pedrozo, J. Díaz-Elizondo, D. Salas, V. Parra, M.T. Núñez, C. Hidalgo, S. Lavandero, Iron induces protection and necrosis in cultured cardiomyocytes: role of reactive oxygen species and nitric oxide, *Free Radic. Biol. Med.* 48 (2010) 526–534.
- [25] C. Ibarra, M. Estrada, L. Carrasco, M. Chiong, J.L. Liberona, C. Cárdenas, G. Díaz-Araya, E. Jaimovich, S. Lavandero, Insulin-like growth factor-1 induces an inositol 1,4,5-trisphosphate-dependent increase in nuclear and cytosolic calcium in cultured rat cardiac myocytes, *J. Biol. Chem.* 279 (2004) 7554–7565.
- [26] D. Rojas-Rivera, J. Díaz-Elizondo, V. Parra, D. Salas, A. Contreras, B. Toro, M. Chiong, C. Olea-Azar, S. Lavandero, Regulatory volume decrease in cardiomyocytes is modulated by calcium influx and reactive oxygen species, *FEBS Lett.* 583 (2009) 3485–3492.
- [27] M. Chiong, Z.V. Wang, Z. Pedrozo, D.J. Cao, R. Troncoso, M. Ibacache, A. Criollo, A. Nemchenko, J.A. Hill, S. Lavandero, Cardiomyocyte death: mechanisms and translational implications, *Cell Death Dis.* 2 (2011) e244.
- [28] D.N. Brindley, B.P.C. Kok, P.C. Kienesberger, R. Lehner, J.R.B. Dyck, Shedding light on the enigma of myocardial lipotoxicity: the involvement of known and putative regulators of fatty acid storage and mobilization, *Am. J. Physiol. Endocrinol. Metab.* 298 (2010) E897–908.
- [29] M. Di Paola, P. Zaccagnino, G. Montedoro, T. Cocco, M. Lorusso, Ceramide induces release of pro-apoptotic proteins from mitochondria by either a Ca<sup>2+</sup>-dependent or a Ca<sup>2+</sup>-independent mechanism, *J. Bioenerg. Biomembr.* 36 (2004) 165–170.
- [30] D. Kong, L. Xu, Y. Yu, W. Zhu, D.W. Andrews, Y. Yoon, T.H. Kuo, Regulation of Ca<sup>2+</sup>-induced permeability transition by Bcl-2 is antagonized by Drp1 and hFis1, *Mol. Cell. Biochem.* 272 (2005) 187–199.
- [31] H. Birbes, S. El Bawab, L.M. Obeid, Y.A. Hannun, Mitochondria and ceramide: intertwined roles in regulation of apoptosis, *Adv. Enzyme Regul.* 42 (2002) 113–129.
- [32] R.A. Rose, N. Hatano, S. Ohya, Y. Imaizumi, W.R. Giles, C-type natriuretic peptide activates a non-selective cation current in acutely isolated rat cardiac fibroblasts via natriuretic peptide C receptor-mediated signalling, *J. Physiol.* 580 (2007) 255–274.
- [33] S.L. Chan, M.P. Mattson, Caspase and calpain substrates: roles in synaptic plasticity and cell death, *J. Neurosci. Res.* 58 (1999) 167–190.
- [34] Z. Pedrozo, N. Torrealba, C. Fernández, D. Gatica, B. Toro, C. Quiroga, A.E. Rodriguez, G. Sánchez, T.G. Gillette, J.A. Hill, P. Donoso, S. Lavandero, Cardiomyocyte ryanodine receptor degradation by chaperone-mediated autophagy, *Cardiovasc. Res.* (2013), <http://dx.doi.org/10.1093/cvr/cvt029>.
- [35] M.A.M. Ali, A. Stepanko, X. Fan, A. Holt, R. Schulz, Calpain inhibitors exhibit matrix metalloproteinase-2 inhibitory activity, *Biochem. Biophys. Res. Commun.* 423 (2012) 1–5.
- [36] J. Inserte, V. Hernando, D. Garcia-Dorado, Contribution of calpains to myocardial ischaemia/reperfusion injury, *Cardiovasc. Res.* 96 (2012) 23–31.
- [37] G. Szabadkai, A.M. Simoni, M. Chami, M.R. Wieckowski, R.J. Youle, R. Rizzuto, Drp-1-dependent division of the mitochondrial network blocks intraorganellar Ca<sup>2+</sup> waves and protects against Ca<sup>2+</sup>-mediated apoptosis, *Mol. Cell* 16 (2004) 59–68.
- [38] T. Yu, J.L. Robotham, Y. Yoon, Increased production of reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphology, *Proc. Natl. Acad. Sci. U. S. A.* 103 (2006) 2653–2658.
- [39] J.-C. Martinou, R.J. Youle, Which came first, the cytochrome c release or the mitochondrial fission? *Cell Death Differ.* 13 (2006) 1291–1295.
- [40] D. Arnoult, Mitochondrial fragmentation in apoptosis, *Trends Cell Biol.* 17 (2007) 6–12.
- [41] V. Eisner, V. Parra, S. Lavandero, C. Hidalgo, E. Jaimovich, Mitochondria fine-tune the slow Ca(2+) transients induced by electrical stimulation of skeletal myotubes, *Cell Calcium* 48 (2010) 358–370.
- [42] L. Füllöp, G. Szanda, B. Enyedi, P. Varnai, A. Spät, The effect of OPA1 on mitochondrial Ca<sup>2+</sup> signaling, *PLoS One* 6 (2011) e25199.
- [43] R. Bravo, J.M. Vicencio, V. Parra, R. Troncoso, J.P. Munoz, M. Bui, C. Quiroga, A.E. Rodriguez, H.E. Verdejo, J. Ferreira, M. Iglewski, M. Chiong, T. Simmen, A. Zorzano, J.A. Hill, B.A. Rothermel, G. Szabadkai, S. Lavandero, Increased ER-mitochondrial coupling promotes mitochondrial respiration and bioenergetics during early phases of ER stress, *J. Cell Sci.* 124 (2011) 2143–2152.
- [44] J.-P. Decuyper, G. Monaco, G. Bultynck, L. Missiaen, H. De Smedt, J.B. Parys, The IP<sub>3</sub> receptor-mitochondria connection in apoptosis and autophagy, *Biochim. Biophys. Acta* 1813 (2011) 1003–1013.
- [45] C. Cárdenas, R.A. Miller, I. Smith, T. Bui, J. Molgó, M. Müller, H. Vais, K.-H. Cheung, J. Yang, I. Parker, C.B. Thompson, M.J. Birnbaum, K.R. Hallows, J.K. Foskett, Essential regulation of cell bioenergetics by constitutive InsP<sub>3</sub> receptor Ca<sup>2+</sup> transfer to mitochondria, *Cell* 142 (2010) 270–283.
- [46] C.A. Hetz, M. Hunn, P. Rojas, V. Torres, L. Leyton, A.F.G. Quest, Caspase-dependent initiation of apoptosis and necrosis by the Fas receptor in lymphoid cells: onset of necrosis is associated with delayed ceramide increase, *J. Cell Sci.* 115 (2002) 4671–4683.
- [47] K. Mengubas, A.A. Fahey, J. Lewin, A.B. Mehta, A.V. Hoffbrand, R.G. Wickremasinghe, Killing of T lymphocytes by synthetic ceramide is by a nonapoptotic mechanism and is abrogated following mitogenic activation, *Exp. Cell Res.* 249 (1999) 116–122.

- [48] L. Thon, H. Möhlig, S. Mathieu, A. Lange, E. Bulanova, S. Winoto-Morbach, S. Schütze, S. Bulfone-Paus, D. Adam, Ceramide mediates caspase-independent programmed cell death, *FASEB J.* 19 (2005) 1945–1956.
- [49] W.H. Kim, C.H. Choi, S.K. Kang, C.H. Kwon, Y.K. Kim, Ceramide induces non-apoptotic cell death in human glioma cells, *Neurochem. Res.* 30 (2005) 969–979.
- [50] T. Granot, D. Milhas, S. Carpentier, A. Dagan, B. Segui, S. Gatt, T. Levade, Caspase-dependent and -independent cell death of Jurkat human leukemia cells induced by novel synthetic ceramide analogs, *Leukemia* 20 (2006) 392–399.
- [51] L. Zitvogel, O. Kepp, G. Kroemer, Decoding cell death signals in inflammation and immunity, *Cell* 140 (2010) 798–804.
- [52] J.C. Goldstein, N.J. Waterhouse, P. Juin, G.I. Evan, D.R. Green, The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant, *Nat. Cell Biol.* 2 (2000) 156–162.
- [53] C. Colina, A. Flores, H. Rojas, A. Acosta, C. Castillo, M.D.R. Garrido, A. Israel, R. DiPolo, G. Benaim, Ceramide increase cytoplasmic  $Ca^{2+}$  concentration in Jurkat T cells by liberation of calcium from intracellular stores and activation of a store-operated calcium channel, *Arch. Biochem. Biophys.* 436 (2005) 333–345.
- [54] G. Bajaj, R.K. Sharma, TNF- $\alpha$ -mediated cardiomyocyte apoptosis involves caspase-12 and calpain, *Biochem. Biophys. Res. Commun.* 345 (2006) 1558–1564.
- [55] B. Ramos, J.M. Lahti, E. Claro, S. Jackowski, Prevalence of necrosis in C2-ceramide-induced cytotoxicity in NB16 neuroblastoma cells, *Mol. Pharmacol.* 64 (2003) 502–511.
- [56] W. Van Blitterswijk, A. Van Der Luit, Ceramide: second messenger or modulator of membrane structure and dynamics? *Biochem. J.* 369 (2003) 199–211.
- [57] M. Di Paola, T. Cocco, M. Lorusso, Ceramide interaction with the respiratory chain of heart mitochondria, *Biochemistry* 39 (2000) 6660–6668.
- [58] A. Santel, S. Frank, Shaping mitochondria: the complex posttranslational regulation of the mitochondrial fission protein DRP1, *IUBMB Life* 60 (2008) 448–455.
- [59] C. Cárdenas, J.K. Foskett, Mitochondrial  $Ca^{2+}$  signals in autophagy, *Cell Calcium* 52 (2012) 44–51.
- [60] S.A. Novgorodov, T.I. Gudz, Ceramide and mitochondria in ischemia/reperfusion, *J. Cardiovasc. Pharmacol.* 53 (2009) 198–208.
- [61] C.C. Lim, C. Zuppinger, X. Guo, G.M. Kuster, M. Helmes, H.M. Eppenberger, T.M. Suter, R. Liao, D.B. Sawyer, Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes, *J. Biol. Chem.* 279 (2004) 8290–8299.
- [62] E. Delpy, S.N. Hatem, N. Andrieu, C. de Vaumas, M. Henaff, C. Rücker-Martin, J.P. Jaffrézou, G. Laurent, T. Levade, J.J. Mercadier, Doxorubicin induces slow ceramide accumulation and late apoptosis in cultured adult rat ventricular myocytes, *Cardiovasc. Res.* 43 (1999) 398–407.